Methods for diagnosing or treating a health condition or optimizing the therapeutic efficacy of CAR-T cell therapy

JP2023548509A5Pending Publication Date: 2024-11-12THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526662
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-04
Filing Date
2021-11-04
Publication Date
2024-11-12

AI Technical Summary

Benefits of technology

【0143】 上述したように、医薬組成物の治療有効量は、疾患または健康状態を有する、有する疑いがある、またはそのリスクがある個体などに投与した場合に、特定の有益な効果を促進するのに十分な量の医薬組成物であり得る。いくつかの実施形態において、有効量は、疾患又は健康状態の症状の発症を予防又は遅延させる、疾患又は健康状態の症状の経過を変化させる(例えば、限定するものではないが、疾患の症状の進行を遅らせる)、又は疾患又は健康状態の症状を逆転させるのに十分な量を含む。任意の所与の事例において、適切な有効量が日常的な実験を用いて当業者によって決定され得ることが理解される

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention generally relates to methods, kits, and systems for diagnosing and / or treating various conditions, e.g., proliferative disorders (such as cancer), that are associated with, inter alia, reduced levels or loss of CD58 expression or molecular alterations in CD58 activity.
Need to check novelty before this filing date? Find Prior Art

Claims

1. detecting whether an expression level of CD58 is reduced or absent, or there is one or more molecular alterations in CD58 activity, in a biological sample obtained from the individual, relative to a baseline expression level of CD58, wherein said detecting comprises contacting said biological sample with a detection reagent, and detecting an interaction in said sample between a CD58-encoding gene or product thereof and the detection reagent, The method is for determining an individual's responsiveness to CAR-T cell therapy, and the method identifies the individual as having reduced responsiveness to treatment with CAR-T cell therapy if the expression level of CD58 is reduced or lost, or at least one of one or more molecular alterations in CD58 activity is detected in the sample, compared to a baseline expression level of CD58; The method further comprises:

2. detecting whether an expression level of CD58 is reduced or absent, or there is one or more molecular alterations in CD58 activity, in a biological sample obtained from the individual, relative to a baseline expression level of CD58, wherein said detecting comprises contacting said biological sample with a detection reagent and detecting an interaction in said sample between a CD58 encoding gene or a product thereof and the detection reagent, The method is for identifying individuals with increased non-responsiveness to CAR-T cell therapy, and the method comprises: (i) selecting an individual as having increased non-responsiveness to treatment with CAR-T cell therapy if at least one of the expression levels of CD58 is reduced or lost compared to a baseline expression level of CD58, or one or more molecular alterations in CD58 activity are detected in the sample; or (ii) selecting the individual as not having an increased non-responsiveness to treatment with CAR-T cell therapy if the expression level of CD58 is not reduced or lost in the sample compared to a baseline expression level of CD58, or one or more molecular alterations in CD58 activity are not detected; The method comprising:

3. detecting whether an expression level of CD58 is reduced or absent, or there is one or more molecular alterations in CD58 activity, in a biological sample obtained from the individual, relative to a baseline expression level of CD58, wherein said detecting comprises contacting said biological sample with a detection reagent and detecting an interaction in said sample between a CD58 encoding gene or a product thereof and the detection reagent, The method is a method for optimizing therapeutic efficacy of a CAR-T cell therapy in an individual, and the method includes identifying a therapeutically effective amount of a CAR-T cell therapy based on the detected interaction between the CD58-encoding gene or a product thereof and the detection reagent. The method comprising:

4. 1. A CAR-T cell therapy for use in a method of treating a disease in an individual, comprising: a) detecting whether the expression level of CD58 is reduced or absent, or there is one or more molecular alterations in CD58 activity, in a biological sample obtained from the individual, compared to a baseline expression level of CD58, comprising contacting the biological sample with a detection reagent and detecting an interaction in the sample between a CD58-encoding gene or product thereof and a detection reagent; b) administering a therapeutically effective amount of a CAR-T cell therapy based on the interaction detected between a CD58 encoding gene or product thereof and said detection reagent: The CAR-T cell therapy comprising:

5. 5. The method of any one of claims 1 to 3 or the CAR-T cell therapy for use according to claim 4, wherein the individual has or is suspected of having a health condition associated with a reduced level or loss of CD58 expression compared to a baseline expression level of CD58, or one or more molecular alterations in CD58 activity.

6. 6. The CAR-T cell therapy method or use of claim 5, further comprising treating the condition.

7. The method of any one of claims 1 to 3 and 5 or the CAR-T cell therapy for use according to any one of claims 4 to 6, wherein the medical condition is a proliferative disorder selected from the group consisting of solid tumor cancer, non-solid tumor cancer, and hematological tumors.

8. 7. The method of any one of claims 1 to 3 and 5 to 6 or the CAR-T cell therapy for use according to any one of claims 4 to 6, wherein the medical condition is cancer, optionally non-Hodgkin's lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, large B-cell lymphoma (LBCL), primary effusion lymphoma, diffuse large B-cell lymphoma, splenic marginal zone lymphoma, MALT (mucosa-associated lymphoid tissue) lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma (NHL), leukemia, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia (B-CLL), hairy cell leukemia, chronic myoblastic leukemia, or myeloma.

9. 9. The method of any one of claims 1 to 3 and 5 to 8 or the CAR-T cell therapy for use according to any one of claims 4 to 8, wherein the one or more molecular alterations in CD58 activity are selected from the group consisting of increased RNA / protein expression, decreased RNA / protein expression, loss of expression, aberrant RNA / protein expression, single nucleotide point mutations (SNPs), single nucleotide variations (SNVs), gene amplifications, gene rearrangements, gene fusions, deletions, frameshift deletions, insertions, InDel mutations, epigenetic changes, amino acid substitutions, and any combination thereof.

10. The method of any one of claims 1 to 3 and 5 to 9 or the CAR-T cell therapy for use according to any one of claims 4 to 9, wherein the one or more molecular alterations comprise loss of CD58 expression, reduced expression of CD58 compared to a baseline expression level of CD58, or expression of a mutant form of CD58.

11. The method of any one of claims 1 to 3 and 5 to 10 or the CAR-T cell therapy for use according to any one of claims 4 to 10, wherein the one or more molecular modifications comprise an amino acid substitution at a position corresponding to K60 in SEQ ID NO:

1.

12. 12. The method or use of claim 11, wherein the amino acid substitution is a Lys-to-Glu substitution (K60E).

13. The method of any one of claims 1 to 3 and 5 to 12 or the CAR-T cell therapy for use according to any one of claims 4 to 12, wherein the one or more molecular modifications comprise an amino acid substitution at a position corresponding to C187 of SEQ ID NO:

1.

14. 14. The method or use of claim 13, wherein the amino acid substitution is a Cys-to-Arg substitution (C187R).

15. The method of any one of claims 1 to 3 and 5 to 14 or the CAR-T cell therapy for use according to any one of claims 4 to 14, wherein the one or more molecular alterations in the CD58 encoding gene or their product comprise a reduced binding affinity of the CD58 protein product to its ligand CD2.

16. 16. The method of any one of claims 1 to 3 and 5 to 15 or the CAR-T cell therapy for use according to any one of claims 4 to 15, wherein detecting the interaction between the CD58 encoding gene or its product and the detection reagent comprises a nucleic acid based analytical assay selected from the group consisting of nucleic acid sequencing, circulating tumor nucleic acid assessment, next generation sequencing (NGS), a nucleic acid amplification based assay, loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), polymerase chain reaction (PCR), real-time PCR, quantitative reverse transcription PCR (qRT-PCR), PCR-RFLP assay, HPLC, mass spectrometry genotyping, nucleic acid hybridization assay, comparative genomic hybridization, fluorescent in-situ hybridization (FISH), restriction enzyme digestion, capillary electrophoresis, and any combination thereof.

17. 17. The method of any one of claims 1 to 3 and 5 to 16 or the CAR-T cell therapy for use according to any one of claims 4 to 16, wherein detecting the interaction between the CD58 encoding gene or its product and the detection reagent comprises a protein-based analytical assay selected from the group consisting of immunohistochemistry (IHC), protein microarray, Western blotting, mass spectrometry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining, multiplex detection assay, and any combination thereof.

18. The method of any one of claims 1 to 3 and 5 to 17 or the CAR-T cell therapy for use of any one of claims 4 to 17, further comprising administering said CAR-T cell therapy to said individual, wherein said CAR-T cell therapy is administered to the individual as a monotherapy or in combination with one or more additional therapies.

19. 20. The method or use of claim 18, wherein the CAR-T cell therapy and / or at least one additional therapy comprises a CAR construct comprising a CD2 signaling domain.

20. 20. The method of any one of claims 1 to 3 and 5 to 19 or the CAR-T cell therapy for use according to any one of claims 4 to 19, wherein the CAR-T cell therapy targets an antigen that is expressed at a low density compared to the density in wild type cells.

21. 1. A CAR construct comprising a CD2 signaling domain for use in a method of treating an individual having a health condition characterized by at least one of: reduced or lost expression of CD58, or one or more molecular alterations in the CD58-encoding gene, The method further comprising: a) detecting whether the expression level of CD58 is reduced or absent compared to a baseline expression level of CD58, or whether there is one or more molecular alterations in a CD58-encoding gene or product thereof, in a biological sample obtained from said individual, said detection comprising contacting said biological sample with a detection reagent and detecting an interaction between the CD58-encoding gene or product thereof and the detection reagent in said sample; b) identifying individuals who are likely to respond to treatment with a CAR construct comprising said CD2 signaling domain when at least one of the following is detected in a sample: a reduced or absent expression level of CD58, or one or more molecular alterations in CD58 activity, compared to a baseline expression level of CD58; and c) administering to an individual identified in step b) as likely to respond to treatment with a CAR construct comprising a CD2 signaling domain said treatment with said CAR construct comprising a CD2 signaling domain: The CAR construct comprising:

22. 1. A CAR construct comprising a CD2 signaling domain for use in a method for treating a health condition in an individual, comprising: The method further comprising: a) detecting whether the expression level of CD58 is reduced or absent, as compared to a baseline expression level of CD58, or whether there is one or more molecular alterations in a CD58-encoding gene or a product thereof, in a biological sample obtained from said individual, said detection comprising contacting said biological sample with a detection reagent and detecting an interaction between the CD58-encoding gene or a product thereof and the detection reagent in said sample; and b) based on the detection of a reduction or loss of expression level of CD58 in step a), or one or more molecular alterations in the CD58-encoding gene, administering to said individual a treatment with a CAR construct comprising said CD2 signaling domain: The CAR construct comprising:

23. 23. The CAR construct for use according to claim 21 or 22, wherein the CAR construct comprising the CD2 signaling domain further comprises an anti-CD19 scFv domain.

24. 24. The CAR construct for use according to any one of claims 21 to 23, wherein the CAR construct comprising the CD2 signalling domain comprises the nucleic acid sequence set forth in SEQ ID NO:

4.

25. The CAR construct for use according to any one of claims 21 to 24, wherein the medical condition is a proliferative disorder selected from the group consisting of solid tumor cancer, non-solid tumor cancer, and hematological tumors.

26. 25. The CAR construct for use according to any one of claims 21 to 24, wherein the medical condition is cancer.

27. 27. The CAR construct for use of claim 26, wherein the cancer is selected from the group consisting of: non-Hodgkin's lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, large B-cell lymphoma (LBCL), primary effusion lymphoma, diffuse large B-cell lymphoma, splenic marginal zone lymphoma, MALT (mucosa-associated lymphoid tissue) lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma (NHL), leukemia, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia (B-CLL), hairy cell leukemia, chronic myoblastic leukemia, or myeloma.

28. 28. The CAR construct for use according to any one of claims 21 to 27, wherein the one or more molecular alterations in CD58 activity are selected from the group consisting of increased RNA / protein expression, decreased RNA / protein expression, loss of expression, aberrant RNA / protein expression, single nucleotide point mutations (SNPs), single nucleotide variations (SNVs), gene amplifications, gene rearrangements, gene fusions, deletions, frameshift deletions, insertions, InDel mutations, epigenetic changes, amino acid substitutions, and any combination thereof.

29. 29. The CAR construct for use according to any one of claims 21 to 28, wherein the one or more molecular modifications comprise loss of CD58 expression, reduced expression of CD58 compared to a baseline expression level of CD58, or expression of a mutant form of CD58.

30. 30. The CAR construct for use according to any one of claims 21 to 29, wherein the one or more molecular modifications comprise an amino acid substitution at a position corresponding to K60 of SEQ ID NO:

1.

31. The CAR construct for use according to claim 30, wherein the amino acid substitution is a Lys-to-Glu substitution (K60E).

32. 32. The CAR construct for use according to any one of claims 21 to 31, wherein the one or more molecular modifications comprise an amino acid substitution at a position corresponding to C187 of SEQ ID NO:

1.

33. The CAR construct for use according to claim 32, wherein the amino acid substitution is a Cys-to-Arg substitution (C187R).

34. 34. A CAR construct for use according to any one of claims 21 to 33, wherein the one or more molecular modifications in the CD58 encoding gene or their product comprise a reduced binding affinity of the CD58 protein product to its ligand CD2.

35. 35. The CAR construct for use according to any one of claims 21 to 34, wherein detecting the interaction between the CD58 encoding gene or its product and the detection reagent comprises a nucleic acid based analytical assay selected from the group consisting of nucleic acid sequencing, circulating tumor nucleic acid assessment, next generation sequencing (NGS), a nucleic acid amplification based assay, loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), polymerase chain reaction (PCR), real-time PCR, quantitative reverse transcription PCR (qRT-PCR), PCR-RFLP assay, HPLC, mass spectrometry genotyping, nucleic acid hybridization assay, comparative genomic hybridization, fluorescent in-situ hybridization (FISH), restriction enzyme digestion, capillary electrophoresis, and any combination thereof.

36. 35. The CAR construct for use according to any one of claims 21 to 34, wherein detecting the interaction between the CD58 encoding gene or its product and the detection reagent comprises a protein-based analytical assay selected from the group consisting of immunohistochemistry (IHC), protein microarray, Western blotting, mass spectrometry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining, multiplex detection assays, and any combination thereof.

37. A kit for the diagnosis and / or treatment of a health condition in an individual, comprising: (i) a reagent for assessing, in a biological sample from the individual, the expression level of CD58, or the presence and / or absence of one or more molecular alterations in the CD58-encoding gene or products thereof; and (ii) containing instructions for their use; The kit.

38. (a) The kit is further designed for determining an individual's responsiveness to CAR-T cell therapy, the determining comprising: i) detecting whether the expression level of CD58 is reduced or absent or there is one or more molecular alterations in the CD58-encoding gene or products thereof in a biological sample obtained from the individual, comprising contacting the biological sample with a detection reagent and detecting an interaction between the CD58-encoding gene or products thereof and the detection reagent in the sample; and ii) identifying the individual as having reduced responsiveness to treatment with CAR-T cell therapy if at least one of the expression level of CD58 is reduced or absent or one or more molecular alterations in CD58 activity is detected in the sample compared to a baseline expression level of CD58; or (b) the kit is further designed to identify an individual having an increased non-responsiveness to CAR-T cell therapy, wherein the identification comprises: i) detecting whether the expression level of CD58 is reduced or absent or there is one or more molecular alterations in the CD58-encoding gene or products thereof in a biological sample obtained from the individual, comprising contacting the biological sample with a detection reagent and detecting an interaction between the CD58-encoding gene or products thereof and the detection reagent in the sample; and ii) selecting the individual as having an increased non-responsiveness to treatment with CAR-T cell therapy if at least one of the expression level of CD58 is reduced or lost compared to a baseline expression level of CD58 or one or more molecular alterations in CD58 activity are detected in the sample, or selecting the individual as not having an increased non-responsiveness to treatment with CAR-T cell therapy if the expression level of CD58 is not reduced or lost compared to a baseline expression level of CD58 or one or more molecular alterations in CD58 activity are not detected in the sample; or (c) the kit is further designed to optimize the therapeutic efficacy of CAR-T cell therapy in an individual, the optimization comprising: i) detecting whether the expression level of CD58 is reduced or absent, as compared to a baseline expression level of CD58, or whether there is one or more molecular alterations in the CD58-encoding gene or products thereof, in a biological sample obtained from the individual, comprising contacting the biological sample with a detection reagent and detecting an interaction between the CD58-encoding gene or products thereof and a detection reagent in the sample; and ii) identifying a therapeutically effective amount of a CAR-T cell therapy based on the detected interaction between the CD58-encoding gene or product thereof and the detection reagent; 38. The kit of claim 37, comprising:

39. (a) the individual has, or is suspected of having, a health condition associated with a reduced level or loss of CD58 expression compared to a baseline expression level of CD58, or one or more molecular alterations in the CD58-encoding gene or its product; and / or (b) the kit is further designed for the treatment of the condition; 39. The kit of claim 37 or 38.

40. The health condition is: i) a proliferative disorder selected from the group consisting of solid tumor cancer, non-solid tumor cancer, and hematological tumors; or ii) cancer; or iii) cancer selected from non-Hodgkin's lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, large B-cell lymphoma (LBCL), primary effusion lymphoma, diffuse large B-cell lymphoma, splenic marginal zone lymphoma, MALT (mucosa-associated lymphoid tissue) lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma (NHL), leukemia, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia (B-CLL), hairy cell leukemia, chronic myoblastic leukemia, and myeloma; The kit according to any one of claims 37 to 39,

41. i) the one or more molecular alterations in the CD58-encoding gene or its product are selected from the group consisting of increased RNA / protein expression, decreased RNA / protein expression, loss of expression, aberrant RNA / protein expression, single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), gene amplification, gene rearrangements, gene fusions, deletions, frameshift deletions, insertions, InDel mutations, epigenetic changes, amino acid substitutions, and any combination thereof; ii) the one or more molecular alterations comprise loss of CD58 expression, reduced expression of CD58 compared to a baseline expression level of CD58, or expression of a mutant form of CD58; iii) the one or more molecular modifications comprise an amino acid substitution at a position corresponding to K60 of SEQ ID NO:1; iv) the one or more molecular modifications comprise a Lys-to-Glu substitution at the position corresponding to K60 of SEQ ID NO:1 (K60E); v) the one or more molecular modifications comprise an amino acid substitution at a position corresponding to C187 of SEQ ID NO:1; vi) the one or more molecular modifications include a Cys-to-Arg substitution at a position corresponding to C187 of SEQ ID NO:1 (C187R); or vii) the one or more molecular modifications in the CD58-encoding gene or product thereof include a reduced binding affinity of the CD58 protein product to its ligand, CD2; The kit according to any one of claims 37 to 40.

42. The method of claim 41, wherein assessing the presence and / or absence of one or more molecular alterations in the CD58-encoding gene or product thereof comprises: i) using a nucleic acid-based analytical assay selected from the group consisting of cancer personalized profiling by deep sequencing (CAPP-seq), nucleic acid sequencing, circulating tumor nucleic acid assessment, next generation sequencing (NGS), nucleic acid amplification-based assays, loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), polymerase chain reaction (PCR), real-time PCR, quantitative reverse transcription PCR (qRT-PCR), PCR-RFLP assay, HPLC, mass spectrometry genotyping, nucleic acid hybridization assays, comparative genomic hybridization, fluorescent in-situ hybridization (FISH), restriction enzyme digestion, capillary electrophoresis, and any combination thereof; or ii) using a protein-based analytical assay selected from the group consisting of immunohistochemistry (IHC), protein microarrays, Western blotting, mass spectrometry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining, multiplex detection assays, and any combination thereof; The kit according to any one of claims 37 to 41, comprising:

43. A kit according to any one of claims 37 to 42, further designed for the treatment of the condition.

44. The kit of any one of claims 38 to 43, wherein the CAR-T cell therapy is administered to an individual as a monotherapy or in combination with one or more additional therapies.

45. The kit described in claim 44, wherein the CAR-T cell therapy and / or at least one additional therapy comprises a CAR construct having a CD2 signaling domain.

46. A kit described in any one of claims 38 to 45, wherein the CAR-T cell therapy targets an antigen that is expressed at a low density compared to the density in wild-type cells.

47. A genetically-based system for diagnosing and / or treating a health condition, comprising: a) a logical processor; b) stored program code executable by a logical processor, which when executed by the processor: i) determining an individual's responsiveness to CAR-T cell therapy; ii) identifying individuals as having increased non-responsiveness to treatment with CAR-T cell therapy; iii) optimizing the therapeutic efficacy of CAR-T cell therapy in an individual; and iv) calculating and administering a therapeutically effective amount of the CAR-T cell therapy to the individual; the stored program code providing operations for performing one or more of: The system comprising:

48. a) further comprising a report engine communicatively coupled to said logical processor, wherein reports generated by said report engine depend on results from execution of said program code, said program code configuring said logical processor to receive a preselected set of data inputs relating to an expression level of CD58 in an organism derived from an individual, or the presence and / or absence of one or more molecular alterations of a CD58-encoding gene or product thereof, in order to assign a relative performance score to the individual's responsiveness to CAR-T cell therapy based at least in part on the preselected set of data inputs; and optionally: i) determining an individual's responsiveness to CAR-T cell therapy; ii) identifying individuals as having increased non-responsiveness to treatment with CAR-T cell therapy; iii) optimizing the therapeutic efficacy of CAR-T cell therapy in an individual; and / or iv) calculating and administering a therapeutically effective amount of the CAR-T cell therapy to the individual; and / or b) generating a report containing information related to the individual identified as having increased non-responsiveness to CAR-T cell therapy and / or related to the CAR-T cell therapy identified as effective in treating a health condition, optionally characterized in that the profile report has an encoding selected from the group consisting of: ".doc"; ".pdf"; ".xml"; ".html"; ".jpg"; ".aspx"; ".php", and any combination thereof.

48. The system of claim 47.

49. When executed, receiving a profile including a preselected set of data inputs; and (a) assigning a relative performance score to the identified CAR-T cell therapy based at least in part on the profile, and outputting a report of the CAR-T cell therapy based on the assigned performance score; or (b) assigning a relative non-responsiveness score to the identified individual based at least in part on the profile, and outputting a report for said individual based on the assigned non-responsiveness score; A non-transitory computer-readable medium containing machine-executable instructions that cause a processor to perform operations including:

50. A report generated by the system or medium described in claim 48 or 49.